Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 3, 2014, Pages 613-631

  Saurat, Thibault ^a,b   Buron, Frédéric ^a   Rodrigues, Nuno ^a   De Tauzia, Marie Ludivine ^b   Colliandre, Lionel ^a   Bourg, Stéphane ^a,b   Bonnet, Pascal ^a   Guillaumet, Gérald ^a   Akssira, Mohamed ^c   Corlu, Anne ^d   Guillouzo, Christiane ^d   Berthier, Pauline ^e   Rio, Pascale ^e   Jourdan, Marie Lise ^e   Bénédetti, Hélène ^b   Routier, Sylvain ^a  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

^c HASSAN II UNIVERSITY   (Morocco)

^d UNIVERSITÉ DE RENNES 1   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROBLASTS; G1 PHASE; HUMANS; ISOENZYMES; MOLECULAR DOCKING SIMULATION; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIDINES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TOR SERINE-THREONINE KINASES;

EID: 84894027640     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401138v     Document Type: Article

References (75)

1. Cantley, L. C. The phosphoinositide 3-kinase pathway Science 2002, 296, 1655-1657
2. Engelman, J. A.; Luo, J.; Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat. Rev. Genet. 2006, 7, 606-619
3. Meier, T. I.; Cook, J. A.; Thomas, J. E.; Radding, J. A.; Horn, C.; Lingaraj, T.; Smith, M. C. Cloning, expression, purification, and characterization of the human class Ia phosphoinositide 3-kinase isoforms Protein Expression Purif. 2004, 35, 218-224
4. Ali, K.; Camps, M.; Pearce, W. P.; Ji, H.; Rückle, T.; Kuehn, N.; Pasquali, C.; Chabert, C.; Rommel, C.; Vanhaesebroeck, B. Isoform-specific functions of phosphoinositide 3-kinases: p110δ but not p110γ promotes optimal allergic responses in vivo J. Immunol. 2008, 180, 2538-2544
5. Ali, K.; Bilancio, A.; Thomas, M.; Pearce, W.; Gilfillan, A. M.; Tkaczyk, C.; Kuehn, N.; Gray, A.; Giddings, J.; Peskett, E.; Fox, R.; Bruce, I.; Walker, C.; Sawyer, C.; Okkenhaug, K.; Finan, P.; Vanhaesebroeck, B. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response Nature 2004, 431, 1007-1011
6. Jackson, S. P.; Schoenwaelder, S. M.; Goncalves, I.; Nesbitt, W. S.; Yap, C. L.; Wright, C. E.; Kenche, V.; Anderson, K. E.; Dopheide, S. M.; Yuan, Y.; Sturgeon, S. A.; Prabaharan, H.; Thompson, P. E.; Smith, G. D.; Shepherd, P. R.; Daniele, N.; Kulkarni, S.; Abbott, B.; Saylik, D.; Jones, C.; Lu, L.; Giuliano, S.; Hughan, S. C.; Angus, J. A.; Robertson, A. D.; Salem, H. H. PI3-kinase p110β: a new target for antithrombotic therapy Nat. Med. 2005, 11, 507-514
7. Hirsch, E.; Katanaev, V. L.; Garlanda, C.; Azzolino, O.; Pirola, L.; Silengo, L.; Sozzani, S.; Mantovani, A.; Altruda, F.; Wymann, M. P. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation Science 2000, 287, 1049-1053
8. Campbell, I. G.; Russell, S. E.; Choong, D. Y. H.; Montgomery, K. G.; Ciavarella, M. L.; Hooi, C. S. F.; Cristiano, B. E.; Pearson, R. B.; Phillips, W. A. Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res. 2004, 64, 7678-7681
9. Kang, S.; Bader, A. G.; Vogt, P. K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 802-807
10. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K. V.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. High frequency of mutations of the PIK3CA gene in human cancers Science 2004, 304, 554
11. Yuan, T. L.; Cantley, L. C. PI3K pathway alterations in cancer: variations on a theme Oncogene 2008, 27, 5497-5510
12. Manning, B. D. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis J. Cell Biol. 2004, 167, 399-403
13. Liu, P.; Cheng, H.; Roberts, T. M.; Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer Nat. Rev. Drug Discovery 2009, 8, 627-644
14. Jiang, B.-H.; Liu, L.-Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment Drug Resist. Updates 2008, 11, 63-76
15. Chalhoub, N.; Baker, S. J. PTEN and the PI3-kinase pathway in cancer Annu. Rev. Pathol. 2009, 4, 127-150
16. O'Reilly, K. E.; Rojo, F.; She, Q.-B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D. J.; Ludwig, D. L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res. 2006, 66, 1500-1508
17. Peng, T.; Golub, T. R.; Sabatini, D. M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation Mol. Cell. Biol. 2002, 22, 5575-5584
18. Shaw, R. J.; Cantley, L. C. Ras, PI3K and mTOR signalling controls tumour cell growth Nature 2006, 441, 424-430
19. Cleary, J. M.; Shapiro, G. I. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer Curr. Oncol. Rep. 2010, 12, 87-94
20. Garcia-Echeverria, C.; Sellers, W. R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer Oncogene 2008, 27, 5511-5526
21. Mahadevan, D.; Chiorean, E. G.; Harris, W. B.; Von Hoff, D. D.; Stejskal-Barnett, A.; Qi, W.; Anthony, S. P.; Younger, A. E.; Rensvold, D. M.; Cordova, F.; Shelton, C. F.; Becker, M. D.; Garlich, J. R.; Durden, D. L.; Ramanathan, R. K. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies Eur. J. Cancer 2012, 48, 3319-3327
22. Chang, K.-Y.; Tsai, S.-Y.; Wu, C.-M.; Yen, C.-J.; Chuang, B.-F.; Chang, J.-Y. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo Clin. Cancer Res. 2011, 17, 7116-7126
23. Cleary, J. M.; Shapiro, G. I. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer Curr. Oncol. Rep. 2010, 12, 87-94
24. Ihle, N. T.; Powis, G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy Mol. Cancer Ther. 2009, 8, 1-9
25. Marone, R.; Cmiljanovic, V.; Giese, B.; Wymann, M. P. Targeting phosphoinositide 3-kinase: moving towards therapy Biochim. Biophys. Acta 2008, 1784, 159-185
26. Yap, T. A.; Garrett, M. D.; Walton, M. I.; Raynaud, F.; De Bono, J. S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises Curr. Opin. Pharmacol. 2008, 8, 393-412
27. Eichhorn, P. J. A.; Gili, M.; Scaltriti, M.; Serra, V.; Guzman, M.; Nijkamp, W.; Beijersbergen, R. L.; Valero, V.; Seoane, J.; Bernards, R.; Baselga, J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235 Cancer Res. 2008, 68, 9221-9230
28. Maira, S.-M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chène, P.; Pover, A. D.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; García-Echeverría, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol. Cancer Ther. 2008, 7, 1851-1863
29. Howes, A. L.; Chiang, G. G.; Lang, E. S.; Ho, C. B.; Powis, G.; Vuori, K.; Abraham, R. T. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures Mol. Cancer Ther. 2007, 6, 2505-2514
30. Phase I Trial of Oral PX-866. http://www.clinicaltrials.gov/ct2/show/ NCT00726583?term=PX866&rank=5 (accessed January 2014).
31. Liu, Q.; Thoreen, C.; Wang, J.; Sabatini, D.; Gray, N. S. mTOR mediated anti-cancer drug discovery Drug Discovery Today: Ther. Strategies 2009, 6, 47-55
32. Apsel, B.; Blair, J. A.; Gonzalez, B.; Nazif, T. M.; Feldman, M. E.; Aizenstein, B.; Hoffman, R.; Williams, R. L.; Shokat, K. M.; Knight, Z. A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases Nat. Chem. Biol. 2008, 4, 691-699
33. Liu, K. K. C.; Huang, X.; Bagrodia, S.; Chen, J. H.; Greasley, S.; Cheng, H.; Sun, S.; Knighton, D.; Rodgers, C.; Rafidi, K.; Zou, A.; Xiao, J.; Yan, S. Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 1270-1274
34. Liu, K. K.-C.; Bagrodia, S.; Bailey, S.; Cheng, H.; Chen, H.; Gao, L.; Greasley, S.; Hoffman, J. E.; Hu, Q.; Johnson, T. O.; Knighton, D.; Liu, Z.; Marx, M. A.; Nambu, M. D.; Ninkovic, S.; Pascual, B.; Rafidi, K.; Rodgers, C. M.-L.; Smith, G. L.; Sun, S.; Wang, H.; Yang, A.; Yuan, J.; Zou, A. 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 6096-6099
35. Cheng, H.; Bagrodia, S.; Bailey, S.; Edwards, M.; Hoffman, J.; Hu, Q.; Kania, R.; Knighton, D. R.; Marx, M. A.; Ninkovic, S.; Sun, S.; Zhang, E. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design MedChemComm 2010, 1, 139
36. Knight, S. D.; Adams, N. D.; Burgess, J. L.; Chaudhari, A. M.; Darcy, M. G.; Donatelli, C. A.; Luengo, J. I.; Newlander, K. A.; Parrish, C. A.; Ridgers, L. H.; Sarpong, M. A.; Schmidt, S. J.; Van Aller, G. S.; Carson, J. D.; Diamond, M. A.; Elkins, P. A.; Gardiner, C. M.; Garver, E.; Gilbert, S. A.; Gontarek, R. R.; Jackson, J. R.; Kershner, K. L.; Luo, L.; Raha, K.; Sherk, C. S.; Sung, C.-M.; Sutton, D.; Tummino, P. J.; Wegrzyn, R. J.; Auger, K. R.; Dhanak, D. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin ACS Med. Chem. Lett. 2010, 1, 39-43
37. Wen, P. Y.; Omuro, A. M.; Batchelor, T. T.; Lai, A.; Mellinghoff, I. K.; Nghiemphu, L.; Norden, A.; Gendreau, S. B.; Laird, A. D.; Nguyen, L.; Cloughesy, T. Abstract B265: a phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma Mol. Cancer Ther. 2009, 8, B265-B265
38. NAr and palladium-catalyzed cross-coupling reactions Synthesis 2009, 2379-2284
39. NAr and palladium-catalyzed reactions Org. Biomol. Chem. 2009, 7, 5113-5118
40. Tikad, A.; Routier, S.; Akssira, M.; Leger, J.-M.; Jarry, C.; Guillaumet, G. New efficient route to dissymmetric 2,4-di(het)aryl-pyrido[3,2- d ]pyrimidines via regioselective cross-coupling reactions Org. Lett. 2007, 9, 4673-4676
41. Tikad, A.; Routier, S.; Akssira, M.; Leger, J.-M.; Jarry, C.; Guillaumet, G. Efficient access to novel mono- and disubstituted pyrido[3,2- d ]pyrimidines Synlett 2006, 1938-1942
42. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Okada, M.; Ohta, M.; Tsukamoto, S.; Parker, P.; Workman, P.; Waterfield, M. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors Bioorg. Med. Chem. 2006, 14, 6847-6858
43. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Kawaguchi, K.; Koizumi, T.; Yamano, M.; Matsuda, K.; Okada, M.; Ohta, M. Preparation of condensed heteroaryl derivatives as phosphatidylinositol 3-kinase inhibitors and anticancer agents. PCT Int. Appl. WO 2001083456 A1 20011108, 2001.
44. Sutherlin, D. P.; Baker, S.; Bisconte, A.; Blaney, P. M.; Brown, A.; Chan, B. K.; Chantry, D.; Castanedo, G.; DePledge, P.; Goldsmith, P.; Goldstein, D. M.; Hancox, T.; Kaur, J.; Knowles, D.; Kondru, R.; Lesnick, J.; Lucas, M. C.; Lewis, C.; Murray, J.; Nadin, A. J.; Nonomiya, J.; Pang, J.; Pegg, N.; Price, S.; Reif, K.; Safina, B. S.; Salphati, L.; Staben, S.; Seward, E. M.; Shuttleworth, S.; Sohal, S.; Sweeney, Z. K.; Ultsch, M.; Waszkowycz, B.; Wei, B. Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf Bioorg. Med. Chem. Lett. 2012, 22, 4296-4302
45. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002) J. Biol. Chem. 1994, 269, 5241-5248
46. Pomel, V.; Gaillard, P.; Desforges, G.; Quattropani, A.; Montagne, C. Preparation of 4-morpholino-pyrido[3,2-d]pyrimidine compounds as PI3K inhibitors for therapeutic applications. PCT Int. Appl. WO 2010037765 A2 20100408, 2010.
47. Castanedo, G.; Chan, B.; Lucas, M.; Safina, B.; Sutherlin, D.; Sweeney, Z. Preparation of pyrido[3,2-d]pyrimidine as PI3kδ inhibitors. PCT Int. Appl. WO 2011101429 A1 20110825, 2011.
48. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J. A.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The identification of 2-(1 H -indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer J. Med. Chem. 2008, 51, 5522-5532
49. Sutherlin, D. P.; Sampath, D.; Berry, M.; Castanedo, G.; Chang, Z.; Chuckowree, I.; Dotson, J.; Folkes, A.; Friedman, L.; Goldsmith, R.; Heffron, T.; Lee, L.; Lesnick, J.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Olivero, A.; Pang, J.; Prior, W. W.; Salphati, L.; Sideris, S.; Tian, Q.; Tsui, V.; Wan, N. C.; Wang, S.; Wiesmann, C.; Wong, S.; Zhu, B.-Y. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer J. Med. Chem. 2010, 53, 1086-1097
50. Ar and palladium-catalyzed coupling reactions Tetrahedron Lett. 2005, 46, 5851-5855
51. Riadi, Y.; Massip, S.; Leger, J. M.; Jarry, C.; Lazar, S.; Guillaumet, G. Convenient synthesis of 2,4-disubstituted pyrido[2,3- d ]pyrimidines via regioselective palladium-catalyzed reactions Tetrahedron 2012, 68, 5018-5024
52. Neagoie, C.; Vedrenne, E.; Buron, F.; Mérour, J.-Y.; Rosca, S.; Bourg, S.; Lozach, O.; Meijer, L.; Baldeyrou, B.; Lansiaux, A.; Routier, S. Synthesis of chromeno[3,4- b ]indoles as lamellarin D analogues: a novel DYRK1A inhibitor class Eur. J. Med. Chem. 2012, 49, 379-396
53. Verheijen, J. C.; Richard, D. J.; Curran, K.; Kaplan, J.; Lefever, M.; Nowak, P.; Malwitz, D. J.; Brooijmans, N.; Toral-Barza, L.; Zhang, W.-G.; Lucas, J.; Hollander, I.; Ayral-Kaloustian, S.; Mansour, T. S.; Yu, K.; Zask, A. Discovery of 4-morpholino-6-aryl-1 H -pyrazolo[3,4- d ]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent J. Med. Chem. 2009, 52, 8010-8024
54. Smith, R.; Thompson, S.; Hosahalli, S.; Bejugam, M.; Nanduri, S.; Panigrahi, S.; Mahalingam, N. Preparation of morpholinylheteroaryl- quinazolinylphenylcarbonylphenylurea derivatives and analogs for use as dual PI3K/mTOR inhibitors. PCT Int. Appl. WO 2012058671 A1 20120503, 2012.
55. Biological Macromolecular Resource. http://www.rcsb.org/pdb/home/home.do (accessed January 2014).
56. Huang, C.-H.; Mandelker, D.; Schmidt-Kittler, O.; Samuels, Y.; Velculescu, V. E.; Kinzler, K. W.; Vogelstein, B.; Gabelli, S. B.; Amzel, L. M. The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations Science 2007, 318, 1744-1748
57. Mandelker, D.; Gabelli, S. B.; Schmidt-Kittler, O.; Zhu, J.; Cheong, I.; Huang, C.-H.; Kinzler, K. W.; Vogelstein, B.; Amzel, L. M. A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 16996-17001
58. Knight, Z. A.; Chiang, G. G.; Alaimo, P. J.; Kenski, D. M.; Ho, C. B.; Coan, K.; Abraham, R. T.; Shokat, K. M. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold Bioorg. Med. Chem. 2004, 12, 4749-4759
59. Zask, A.; Verheijen, J. C.; Curran, K.; Kaplan, J.; Richard, D. J.; Nowak, P.; Malwitz, D. J.; Brooijmans, N.; Bard, J.; Svenson, K.; Lucas, J.; Toral-Barza, L.; Zhang, W.-G.; Hollander, I.; Gibbons, J. J.; Abraham, R. T.; Ayral-Kaloustian, S.; Mansour, T. S.; Yu, K. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines J. Med. Chem. 2009, 52, 5013-5016
60. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749
61. Nakabayashi, H.; Taketa, K.; Miyano, K.; Yamane, T.; Sato, J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium Cancer Res. 1982, 42, 3858-3863
62. Nakanishi, K.; Fujimoto, J.; Ueki, T.; Kishimoto, K.; Hashimoto-Tamaoki, T.; Furuyama, J.; Itoh, T.; Sasaki, Y.; Okamoto, E. Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase Clin. Exp. Metastasis 1999, 17, 507-514
63. Gedaly, R.; Angulo, P.; Hundley, J.; Daily, M. F.; Chen, C.; Koch, A.; Evers, B. M. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways Anticancer Res. 2010, 30, 4951-4958
64. Ivison, S. M.; Khan, M. A. S.; Graham, N. R.; Shobab, L. A.; Yao, Y.; Kifayet, A.; Sly, L. M.; Steiner, T. S. The p110α and p110β isoforms of class I phosphatidylinositol 3-kinase are involved in Toll-like receptor 5 signaling in epithelial cells Mediators Inflammation 2010, 1-12
65. Langlois, M.-J.; Bergeron, S.; Bernatchez, G.; Boudreau, F.; Saucier, C.; Perreault, N.; Carrier, J. C.; Rivard, N. The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression PLoS One 2010, 5, e15742
66. Mordant, P.; Loriot, Y.; Leteur, C.; Calderaro, J.; Bourhis, J.; Wislez, M.; Soria, J.-C.; Deutsch, E. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (everolimus) in combination Mol. Cancer Ther. 2010, 9, 358-368
67. Bénistant, C.; Chapuis, H.; Roche, S. A specific function for phosphatidylinositol 3-kinase α (p85α-p110α) in cell survival and for phosphatidylinositol 3-kinase β (p85α-p110β) in de novo DNA synthesis of human colon carcinoma cells Oncogene 2000, 19, 5083-5090
68. Calay, D.; Vind-Kezunovic, D.; Frankart, A.; Lambert, S.; Poumay, Y.; Gniadecki, R. Inhibition of Akt signaling by exclusion from lipid rafts in normal and transformed epidermal keratinocytes J. Invest. Dermatol. 2010, 130, 1136-1145
69. Hollestelle, A.; Elstrodt, F.; Nagel, J. H. A.; Kallemeijn, W. W.; Schutte, M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines Mol. Cancer Res. 2007, 5, 195-201
70. Clark, A. S.; West, K.; Streicher, S.; Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells Mol. Cancer Ther. 2002, 1, 707-717
71. Maestro, version 9.1, Glide, version 5.6, MacroModel, version 9.8, Schrödinger, LLC, New York, 2010.
72. Marvin 5.3.6, ChemAxon, 2010. http://www.chemaxon.com (accessed January 2014).
73. Sadowski, J.; Gasteiger, J. From atoms and bonds to three-dimensional atomic coordinates: automatic model builders Chem. Rev. 1993, 93, 2567-2581
74. CORINA-Fast Generation of High-Quality 3D Molecular Models. http://www.molecular-networks.com/products/corina (accessed January 2014).
75. Barascu, A.; Besson, P.; Le Floch, O.; Bougnoux, P.; Jourdan, M.-L. CDK1-cyclin B1 mediates the inhibition of proliferation induced by omega-3 fatty acids in MDA-MB-231 breast cancer cells Int. J. Biochem. Cell Biol. 2006, 38, 196-208